Inmune Bio, Inc.

INMB

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
SEC CIK: 0001711754

SEC filings (opens in a new tab)

No open-market purchases or sales by Inmune Bio, Inc. insiders were filed in the last 90 days; 82 institutions reported holding it in 13F filings for Q2 2026, worth $7.08M in total; no superinvestor holds it.

Q2 2023 vs. Q1 2023

How the institutions holding Inmune Bio, Inc. changed between Q1 2023 and Q2 2023.

All holders in Q2 2023 All holders in Q1 2023

13F holders of INMB: Q1 2023 compared with Q2 2023
Measure	Q1 2023	Q2 2023	Change
Holders	35	34	−1
Shares	1.81M	2.19M	+380.5K (+21.1%)
Value	$11.7M	$18.2M	+$6.55M (+56.1%)

New holders (2)

Institutions that held Inmune Bio, Inc. at the end of Q2 2023 but not at the end of Q1 2023.

Institutions new to INMB in Q2 2023
Institution	Shares	Value	% of portfolio
Rhenman & Partners Asset Management AB	178,284	$1.62M	0.17%
Meitav Dash Investments Ltd	181,140	–	–

Sold out (3)

Institutions that held Inmune Bio, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.

Institutions that sold out of INMB in Q2 2023
Institution	Shares, Q1 2023	Value, Q1 2023
Squarepoint Ops LLC	13,045	$84.3K
Financial Advocates Investment Management	11,500	$74.3K
Advisory Services Network, LLC	90	$581